More α-SMA+ cells were recruited into tumor sites of mice that received the combined modality therapy, and the level of coverage of CD31+ cells by α-SMA+ pericytes was significantly higher than those recorded in the other three groups (Figure 3F). Here, PECAM1 is linked to neoplasm.